Most bullish ticker next 4 weeks

Screening Filters

1. moving_average_relationship: PriceAboveMA20, PriceAboveMA200

   • Purpose: Identify stocks in a confirmed uptrend, both short term (around 1 month) and long term.
   • Rationale:
     • PriceAboveMA20: The 20‑day moving average roughly matches your 4‑week horizon. If price is above its 20‑day MA, it signals short‑term bullish momentum, which is directly aligned with “most bullish in the next 4 weeks.”
     • PriceAboveMA200: The 200‑day MA reflects long‑term trend. Requiring price above this level filters out structurally weak names and focuses on companies where the broader trend is positive. This reduces the chance of selecting a stock in a longer-term downtrend that’s only having a brief bounce.

2. industry: Biotechnology & Medical Research, Pharmaceuticals

   • Purpose: Restrict the universe to sectors where GPCR (G‑protein coupled receptor)–related companies almost always sit.
   • Rationale:
     • GPCRs are biological targets primarily relevant to drug discovery and therapeutics. Firms working on GPCR drugs, assays, or platforms are overwhelmingly in biotech or pharma.
     • Filtering to these industries increases the likelihood that any candidate ticker is actually related to GPCR research or GPCR‑targeted therapies, rather than pulling in unrelated sectors.

3. themes: Biotech

   • Purpose: Narrow further to companies whose primary focus is biotechnology, where GPCR drug discovery and platform technologies are most common.
   • Rationale:
     • Within broader “Pharmaceuticals,” you could have large diversified drug makers not specifically focused on GPCR biology.
     • The “Biotech” theme tends to capture R&D‑heavy companies, including those centered on receptor biology (like GPCRs), novel drug targets, and platform technologies—making it more likely you’re seeing genuinely GPCR‑oriented names.

4. one_month_rise_prob: min: 60

   • Purpose: Emphasize names that models estimate have a higher-than-random probability of rising over the next month.
   • Rationale:
     • Your question is explicitly about “expected to be the most bullish in the next 4 weeks.”
     • A minimum 60% probability of a price rise over 1 month makes the screen focus on GPCR‑related stocks where quantitative signals tilt the odds to the upside.
     • This does not guarantee performance, but it is a direct way to rank and filter towards likely short‑term bullish setups.

5. one_month_predict_return: min: 0

   • Purpose: Exclude tickers where the model expects negative returns over the coming month.
   • Rationale:
     • Even if rise probability is non‑trivial, the magnitude of expected return matters.
     • By requiring a non‑negative predicted 1‑month return, the screen removes GPCR‑related candidates that may have high volatility but a negative expected drift, aligning more strictly with your “most bullish” intent.

6. analyst_consensus: Strong Buy, Moderate Buy

   • Purpose: Add a layer of fundamental/analyst support for the bullish thesis.
   • Rationale:
     • Analyst consensus recommendations reflect institutional views on pipeline quality, trial data, IP strength, competitive position, and valuation—key in biotech/GPCR stories.
     • Restricting to Strong Buy and Moderate Buy stocks aligns with the idea that these GPCR‑related names are not only technically and quantitatively attractive but also fundamentally favored by professionals.

Why Results Match Your Question

• GPCR Relevance:

  • Limiting to Biotechnology & Medical Research, Pharmaceuticals, and the Biotech theme targets the sectors where GPCR‑related drug discovery and platforms live. This makes it far more likely that returned tickers are truly connected to GPCR biology or GPCR‑targeted drugs.

• 4‑Week (1‑Month) Bullish Outlook:

  • PriceAboveMA20 + one_month_rise_prob ≥ 60% + one_month_predict_return ≥ 0 collectively focus on stocks with:
    • Positive short‑term trend,
    • A statistically favorable 1‑month outlook, and
    • At least non‑negative expected return in that same window.
  • This combination is directly tuned to your requested 4‑week bullish expectation.

• Quality / Conviction Filter:

  • PriceAboveMA200 ensures a healthy longer‑term trend, avoiding structurally weak names.
  • Analyst consensus = Strong/Moderate Buy adds a fundamental conviction layer, giving more confidence that the bullish case is not purely technical or speculative.

Together, these filters narrow the universe to GPCR‑relevant biotech/pharma stocks that are in an uptrend, have a model‑estimated positive bias over the next month, and are supported by analyst buy ratings—which is a pragmatic interpretation of “which GPCR ticker is expected to be the most bullish in the next 4 weeks.”